Defective mismatch repair and benefit from bevacizumab for colon cancer: Findings from NSABP C-08

Journal of the National Cancer Institute

Volumn 105, Issue 13, 2013, Pages 989-992

  Pogue Geile, Kay ^a   Yothers, Greg ^a,b   Taniyama, Yusuke ^a   Tanaka, Noriko ^a   Gavin, Patrick ^a   Colangelo, Linda ^a,b   Blackmon, Nicole ^a   Lipchik, Corey ^a   Kim, Seong Rim ^a   Sharif, Saima ^a,c   Allegra, Carmen ^a,d   Petrelli, Nicholas ^a,e   O'Connell, Michael J ^a   Wolmark, Norman ^a,c   Paik, Soonmyung ^a,f  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e HELEN F GRAHAM CANCER CENTER   (United States)

^f Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; OXALIPLATIN; PROTEIN MSH2; PROTEIN MSH3;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; EXOME; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MORTALITY; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; VALIDATION STUDY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS B-RAF; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880239195     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt140     Document Type: Article

References (16)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
2. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluo-rouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23(15):3502-3508.
3. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucov-orin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21(1):60-65.
4. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23(16): 3706-3712.
5. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29(1): 11-16.
6. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyp-ing colorectal tumors. J Clin Oncol. 2002;20(4): 1043-1048.
7. Gavin PG, Yothers G, Tanaka N, et al. BRAF mutation. Clin Cancer Res. 2012;18(23): 6531-6541.
8. Fumagalli D, Gavin PG, Taniyama Y, et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 2010;10:101.
9. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337.
10. Saeterdal I, Bjorheim J, Lislerud K, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A. 2001;98(23):13255-13260.
11. Banejea A, Hands RE, Powar M P, et al. Microsatellite and choromosomal stable colorectal cancers demonstrate poor immu-nogenicity and early disease recurrence. Colorectal Dis. 2009; 11(6):601-608.
12. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97(5):1427-1434.
13. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096-1103.
14. Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101(12):4878-4886.
15. Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol. 1998;160(3):1224-1232.
16. Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73(2): 539-549.